Antonio Diez-Juan1, Carmen Rubio2, Carlos Marin3, Sebastian Martinez3, Nasser Al-Asmar4, Marcia Riboldi5, Patricia Díaz-Gimeno6, Diana Valbuena3, Carlos Simón7. 1. Igenomix Europe, Valencia, Spain. Electronic address: antonio.diez@igenomix.com. 2. Igenomix Europe, Valencia, Spain; Igenomix USA, Miami, Florida. 3. Igenomix Europe, Valencia, Spain. 4. Igenomix USA, Miami, Florida. 5. Igenomix Brasil, São Paulo, Brazil. 6. Fundación Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics and Gynecology, School of Medicine, Valencia University and Instituto Universitario IVI/INCLIVA, Valencia, Spain. 7. Igenomix Europe, Valencia, Spain; Igenomix USA, Miami, Florida; Igenomix Brasil, São Paulo, Brazil; Fundación Instituto Valenciano de Infertilidad (FIVI), Department of Obstetrics and Gynecology, School of Medicine, Valencia University and Instituto Universitario IVI/INCLIVA, Valencia, Spain.
Abstract
OBJECTIVE: To investigate the clinical relevance of mitochondrial DNA (mtDNA) content as a viability score in human euploid embryos. DESIGN: Retrospective analysis of mtDNA content of transferred euploid embryos. SETTING: Reproductive genetics laboratory. PATIENT(S): Single-embryo transfer in 270 patients who underwent preimplantation genetic screening (205 day-3 blastomere biopsies, and 65 day-5 trophectoderm biopsies), and 10 patients with double-embryo transfer (male-female). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Normalized mtDNA content versus nuclear DNA (nDNA) from transferred euploid embryos. RESULT(S): A high mtDNA copy number in euploid embryos is indicative of lower embryo viability and implantation. Using the normalized mtDNA content, we created the mitochondrial score or Mitoscore (Ms). Day-3 embryos with <34 (MsA) had an implantation rate (IR) of 59% (n = 51); those with 34-52 (MsB) had an IR of 44% (n = 52); those with 52-97 (MsC) had an IR of 42% (n = 50); and those with >97 (MsD) had an IR of 25% (n = 52). Embryos with Ms >160 (n = 22) never implanted. Day-5 embryos with <18.19 (MsA) had an IR of 81%; those with 18.19-24.15 (MsB) had an IR of 50% (n = 16); those with 24.15-50.58 (MsC) had an IR of 62% (n = 16); and those with levels >50.58 (MsD) had an IR of 18% (n = 17). Embryos with levels >60 (n = 7) never implanted. CONCLUSION(S): An increased amount of mtDNA in euploid embryos is related to poor implantation potential and may be indicative of reduced metabolic fuel during oocyte maturation. We are implementing Ms in our preimplantation genetic screening platform to prospectively analyze its clinical relevance.
OBJECTIVE: To investigate the clinical relevance of mitochondrial DNA (mtDNA) content as a viability score in human euploid embryos. DESIGN: Retrospective analysis of mtDNA content of transferred euploid embryos. SETTING: Reproductive genetics laboratory. PATIENT(S): Single-embryo transfer in 270 patients who underwent preimplantation genetic screening (205 day-3 blastomere biopsies, and 65 day-5 trophectoderm biopsies), and 10 patients with double-embryo transfer (male-female). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Normalized mtDNA content versus nuclear DNA (nDNA) from transferred euploid embryos. RESULT(S): A high mtDNA copy number in euploid embryos is indicative of lower embryo viability and implantation. Using the normalized mtDNA content, we created the mitochondrial score or Mitoscore (Ms). Day-3 embryos with <34 (MsA) had an implantation rate (IR) of 59% (n = 51); those with 34-52 (MsB) had an IR of 44% (n = 52); those with 52-97 (MsC) had an IR of 42% (n = 50); and those with >97 (MsD) had an IR of 25% (n = 52). Embryos with Ms >160 (n = 22) never implanted. Day-5 embryos with <18.19 (MsA) had an IR of 81%; those with 18.19-24.15 (MsB) had an IR of 50% (n = 16); those with 24.15-50.58 (MsC) had an IR of 62% (n = 16); and those with levels >50.58 (MsD) had an IR of 18% (n = 17). Embryos with levels >60 (n = 7) never implanted. CONCLUSION(S): An increased amount of mtDNA in euploid embryos is related to poor implantation potential and may be indicative of reduced metabolic fuel during oocyte maturation. We are implementing Ms in our preimplantation genetic screening platform to prospectively analyze its clinical relevance.
Authors: Amber M Klimczak; Lucia E Pacheco; Kelsey E Lewis; Niloofar Massahi; Jon P Richards; William G Kearns; Antonio F Saad; John R Crochet Journal: J Assist Reprod Genet Date: 2018-03-05 Impact factor: 3.412
Authors: Neelke De Munck; Alberto Liñán; Ibrahim Elkhatib; Aşina Bayram; Ana Arnanz; Carmen Rubio; Nicolas Garrido; Barbara Lawrenz; Human M Fatemi Journal: J Assist Reprod Genet Date: 2019-08-07 Impact factor: 3.412